Orexigen Therapeutics Inc.
Orexigen said the 729-patient trial found that 60.4% of obese people given the highest dose of the drug lost at least 5% of their body weight, compared with 14.7% of patients given a placebo. The 24-week trial also found that patients treated with Empatic had mean weight loss of 7.5%, compared with 1.4% for the placebo group.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CORPORATE; Empatic|
|Article Type:||Brief article|
|Date:||Oct 5, 2009|
|Previous Article:||Bristol-Myers Squibb Co.|
|Next Article:||Onyx Pharmaceuticals Inc.|